Documentos de Académico
Documentos de Profesional
Documentos de Cultura
293
Actualización en Obstetricia y Ginecología
294
Avances en Reproducción Humana
295
Actualización en Obstetricia y Ginecología
296
Avances en Reproducción Humana
297
Actualización en Obstetricia y Ginecología
298
Avances en Reproducción Humana
Metformina
Se administra vía oral y es soluble en agua, origina detención hepática
de la neoglucogénesis, disminución de la absorción intestinal de glucosa y
aumento de la captación y utilización periférica de glucosa. A diferencia de las
sulfonilureas, la metformina no modifica la secreción de insulina por el
páncreas. Además, la metformina se asocia con una mejora de la sensibilidad a
la insulina, disminución del colesterol sérico, triglicéridos y presión arterial, así
como una disminución del PAI-155
299
Actualización en Obstetricia y Ginecología
300
Avances en Reproducción Humana
301
Actualización en Obstetricia y Ginecología
302
Avances en Reproducción Humana
Cuestiones no resueltas
Precisando una idea apuntada, existen cuestiones no resueltas acerca
del uso de fármacos sensibilizadores de la acción de la insulina en pacientes
con SOP, derivadas de la heterogeneidad en el concepto y en el diseño
metodológico de la literatura revisada. Aún cuando el uso de estos fármacos en
mujeres con SOP, con o sin deseos reproductivos, pueda parecer razonable, la
disciplina de la MBE exige que se despejen las siguientes incógnitas:
§ No existen evidencias fuertes de algunos de los datos expuestos en el
cuadro 7
§ No está claro si las acciones descritas son consecuencia de la pérdida
de peso
§ La efectividad de la metformina en el tratamiento del SOP necesita de
estudios más amplios y mejor diseñados
§ La teratogenicidad de los fármacos sensibilizadores de la insulina
§ Aunque existan indicios muy fuertes, no existe evidencia de su
capacidad para corregir los riesgos cardiovasculares a largo plazo en
mujeres con SOP
§ Cuáles son los resultados con otras drogas más modernas
303
Actualización en Obstetricia y Ginecología
BIBLIOGRAFÍA
1. Lobo RA, Carmina E. The importance of diagnosing the polycystic ovary syndrome. Ann
Intern Med 2000; 132: 989-993.
2. Nestler JE. Polycystic ovary syndrome: a disorder for the generalist. Fertil Steril 1998; 70:
811-812.
3. Holte J, Bergh T, Berne C, Berglund L Lithell H. Enhanced early insulin response to gin
relation to insulin resistance in women wih polycystic ovary syndrome and normal glucose
tolerance. J Clin Endocrinol Metab 1994; 78: 1052-58.
4. Conway GS. Insulin resistance and obesity in the polycystic ovarian syndrome. En:
Homburg R, editor. Ovario poliquístico. Madrid, Panamericana 1998; Cuad Med Reprod
(Pellicer A, Simón C, editores); 4: 121-32.
5. O’ Brien SN, Welter BH, Mantzke KA, Price TM. Identification of progesterone receptor in
human subcutaneous adipose tissue. J Clin Endocrinol Metab 1998; 83: 509-13.
6. Geisthövel F, Meysing A, Brabant G. C-peptide and insulin, but not C19-steroids, support
the predictive value of body mass index on leptin in serum of premenopausal women.
Human Reprod 1998; 13: 547-53.
7. Gennarelli G, Holte J, Wide L, Berne C, Lithell H. Is there a role for leptin in the endocrine
and metabolic aberrations of polycystic ovary syndrome?. Hum Reprod 1998; 13:535-41.
8. Mantzoros CS, Dunaif A, Flier JS. Leptin concentrations in the polycystic ovary syndrome. J
Clin Endocrinol Metab 1997; 82: 1687-91.
9. Castracane VD, Kraemer RR, Franken MA, Kraemer GR, Gimpel T. Serum leptin
concentration in women: effect of age, obesity, and estrogen administration. Fertil Steril
1998; 70: 472-7.
10. Messinis IE, Milingos S, Zikopoulos K, Kollios G, Seferiadis K, Lolis D. Leptin
concentrations in the follicular phase of spontaneous cycles and cycles superovulated with
follicle stimulating hormone. Hum Reprod 1998; 13: 1152-56.
11. Franks S. Genetic factors in the aetiology of polycystic ovarian syndrome. En: Ovario
Poliquístico. Cuad Med Reprod 1998; 4: 45-58.
12. Dunaif A. Insulin resistance and ovarian dysfunction. En: Moller D, editors Insulin
Resistance. Nueva York, John Wiley, 1993; 301-325.
13. Kiddy DS, Hamilton-Fairley D, Bush A, Short F, Anyaoku , Reed MJ et al. Improvement in
endocrine and ovarian function during dietary treatment of obese women with polycystic
ovary syndrome. Clin Endocrinol 1992; 36: 105-11.
14. Conway GS, Jacobs HS, Holly JMP, Wass JAS. Effects of luteinising hormone, insulin,
insulin-like growth factor I and insulin-like growth factor small binding protein in the
polycystic ovary syndrome. Clin Endocrinol 1990; 33: 593-603.
15. Espinós Gómez JJ. Aspectos metabólicos del Síndrome de ovarios poliquísticos.
Endocrinol 1995; 42: 226-30.
16. Dunaif A, Segal KR, Futterweit W, Dobrjans-Ky A. Profound peripheral insulin resistance,
independent of obesity, in polycystic ovary syndrome. Diabetes 1989; 38: 1165-74.
17. Padrón Durán RS, Fernández GM, Más Dïaz J, González R, Seuc Jo A. Insulinorresistencia
e hiperinsulinismo en mujeres con hiperandrogenismo. Endocrinol 1996; 43: 332-6.
18. Dale PO, Tanbo T, Djoseland O, Jervell J, Abyholm T. Persistence of hyperinsulinemia in
polycystic ovary syndrome after ovarian suppression by gonadotrophin-releasing hormone
agonist. Acta Endocrinol (Copenh) 19992; 126: 132-6.
19. Lemieux S, Lewis GF, Ben-Chetrit A, Steiner G, Greenblatt EM. Correction of
hyperandrogenemia by laparoscopic ovarian cautery in women with polycystic ovarian
syndrome is not accompanied by improved insulin sensitivity or lipid-lipoprotein levels. J
Clin Endocrinol Metab 1999; 84: 4278-82.
20. Adashi EY, Hsueh AJW, Yen SSC. Insulin enhancement of luteinizing hormone and follicle-
stimulating hormone release by cultured pituitary cells. Endocrinology 1981; 108: 1441-49.
21. Conway GS, Agrawal R, Betteridge DJ, Jacobs HS. Risk factors for coronary artery disease
in lean and obese women with the polycystic ovary syndrome. Clin Endocrinol 1992; 37:
119-25.
22. Elkind-Hirsch KE, McWilliams RB. Pregnancy after treatment with the insulin-sensitizing
agent troglitazone in an obese woman with the hyperandrogenic, insulin-resistant
acanthosis nigricans syndrome.Fertil Steril 1999; 71: 943-47.
304
Avances en Reproducción Humana
305
Actualización en Obstetricia y Ginecología
43. Wild RA, Alaupovic P, Parker IJ. Lipid and apolipoprotein abnormalities in hirsute women. I.
The association with insulin resistance. Am J Obstet Gynecol. 1992 Apr;166(4):1191-6;
44. Wild RA, Alaupovic P, Givens JR, Parker IJ. Lipoprotein abnormalities in hirsute women. II.
Compensatory responses of insulin resistance and dehydroepiandrosterone sulfate with
obesity. Am J Obstet Gynecol. 1992 Dec;167(6):1813-8.
45. Remsberg KE, Talbott EO, Zborowski JV, Evans RW, McHugh-Pemu K. Evidence for
competing effects of body mass, hyperinsulinemia, insulin resistance, and androgens on
leptin levels among lean, overweight, and obese women with polycystic ovary syndrome.
Fertil Steril. 2002 Sep;78(3):479-86.
46. Talbott EO, Guzick DS, Sutton-Tyrrell K, McHugh-Pemu KP, Zborowski JV, Remsberg KE,
Kuller LH. Evidence for association between polycystic ovary syndrome and premature
carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol. 2000
Nov; 20(11):2414-21.
47. Talbott E, Clerici A, Berga SL, Kuller L, Guzick D, Detre K, Daniels T, Engberg RA. Adverse
lipid and coronary heart disease risk profiles in young women with polycystic ovary
syndrome: results of a case-control study. J Clin Epidemiol. 1998 May;51(5):415-22.
48. Velazquez M E, Bellabarba GA, Mendoza S, Sanchez L. Postprandial triglyceride response
in patients with polycystic ovary syndrome: relationship withwaist-to-hip ratio and insulin.
Fertil Steril. 2000 Dec;74(6):1159-63.
49. Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women
with polycystic ovary syndrome. Am J Med. 2001 Dec 1;111(8):607-13.
50. Remsberg KE, Talbott EO, Zborowski JV, Evans RW, McHugh-Pemu K. Evidence for
competing effects of body mass, hyperinsulinemia, insulin resistance, and androgens on
leptin levels among lean, overweight, and obese women with polycystic ovary syndrome.
Fertil Steril. 2002 Sep;78(3):479-86.
51. Talbott EO, Guzick DS, Sutton-Tyrrell K, McHugh-Pemu KP, Zborowski JV, Remsberg KE,
Kuller LH. Evidence for association between polycystic ovary syndrome and premature
carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol. 2000
Nov;20(11):2414-21.
52. Talbott E, Clerici A, Berga SL, Kuller L, Guzick D, Detre K, Daniels T, Engberg RA. Adverse
lipid and coronary heart disease risk profiles in young women with polycystic ovary
syndrome: results of a case-control study. J Clin Epidemiol. 1998 May;51(5):415-22.
53. Talbott E, Guzick D, Clerici A, Berga S, Detre K, Weimer K, Kuller L. Coronary heart
disease risk factors in women with polycystic ovary syndrome. Arterioscler Thromb Vasc
Biol. 1995 Jul;15(7):821-6.
54. Birdsall MA, Farquhar CM, White HD. Association between polycystic ovaries and extent of
coronary artery disease in women havi ng cardiac catheterization. Ann Intern Med. 1997 Jan
1;126(1):32-5.
55. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med 2002; 137:
25-33.
56. Norman RJ, Kidson WJ, Cuneo RC, Zacharin MR. Metformin and intervention in polycystic
ovary syndrome. Endocrine Society of Australia, the Australian Diabetes Society and the
Australian Paediatric Endocrine Group. Med J Aust. 2001 Jun 4;174(11):580-3.
57. Huber-Buchholz MM, Carey DG, Norman RJ. Restoration of reproductive potential by
lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and
luteinizing hormone. J Clin Endocrinol Metab 1999; 84: 1470-1474.
58. Ehrmann DA, Schneider DJ, Sobel BE, et al. Troglitazone improves defects in insulin
action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic
ovary syndrome. J Clin Endocrinol Metab 1997; 82: 2108-2116.
59. Acbay O, Gundogdu S. Can metformin reduce insulin resistance in polycystic ovary
syndrome? Fertil Steril 1996; 65: 946-949.
60. Crave JC, Fimbel S, Lejeune H, et al. Effects of diet and metformin administration on sex
hormone-binding globulin, androgens, and insulin in hirsute and obese women. J Clin
Endocrinol Metab 1995; 80: 2057-2062.
61. Nestler JE, Jakubowicz DJ. Lean women with polycystic ovary syndrome respond to insulin
reduction with decreases in ovarian P450c17 alpha activity and serum androgens. J Clin
Endocrinol Metab 1997; 82: 4075-4079.
62. Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R. Effects of metformin on spontaneous
and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 1998;
338: 1876-1880.
306
Avances en Reproducción Humana
307
Actualización en Obstetricia y Ginecología
308